Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM201 plus chemotherapy in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia
MOH_2019-02-20_005945Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of siremadlin in acute myeloid leukemia (AML) (4 cohorts), sponsored by Novartis. Primary endpoints: Recommended dose for expansion and Recommended phase 3 dose confirmation. Started Dec 2018; status: completed.
02
Drugs
siremadlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2019-02-20_005945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-20_005945.